Cathelicidins have direct antiviral activity against respiratory syncytial virus in vitro and protective function in vivo in mice and humans.

Silke M Currie, Emily Gwyer Findlay, Amanda McFarlane, Paul Fitch, Agnes Boettcher, Nick Colegrave, Allan Paras, Agnieszka Jozwik, Christopher Chiu, Jürgen Schwarze, Donald J. Davidson

Research output: Contribution to journalArticlepeer-review

Abstract

Respiratory syncytial virus (RSV) is a leading cause of respiratory tract
infection in infants, causing significant morbidity and mortality. No vaccine or specific, effective treatment is currently available. A more complete understanding of the key components of effective host response to RSV, and novel preventative and therapeutic interventions, are urgently required. Cathelicidins are host defence peptides, expressed in the inflamed lung, with key microbicidal and modulatory roles in innate host defence against infection. Here we demonstrate that the human cathelicidin LL-37 mediates an antiviral effect on RSV by inducing direct damage to the viral envelope, disrupting viral particles and decreasing virus binding to, and infection of, human epithelial cells in vitro. In addition, exogenously applied LL-37 is protective against RSV-mediated disease in vivo, in a murine model of pulmonary RSV infection, demonstrating maximal efficacy when applied concomitantly with virus. Furthermore, endogenous murine cathelicidin, induced by infection, has a fundamental role in protection against disease in vivo following infection with RSV. Finally, higher nasal levels of LL-37 are associated with protection in a healthy human adult RSV infection model. These data lead us to propose that cathelicidins are a key, non-redundant component of host defence against pulmonary infection with RSV; functioning as a first point of contact “antiviral shield”, and having additional later phase roles in minimising the severity of disease outcome. Consequently, cathelicidins represent an inducible target for preventative strategies against RSV infection and may inform the design of novel therapeutic analogues for use in established infection.
Original languageEnglish
Pages (from-to)2699-2710
Number of pages11
JournalJournal of Immunology
Volume196
Issue number6
Early online date12 Feb 2016
DOIs
Publication statusE-pub ahead of print - 12 Feb 2016

Keywords

  • Respiratory Syncytial Virus
  • LL-37
  • hCAP-18
  • Cathelicidin
  • mCRAMP
  • Host Defence Peptide
  • Antimicrobial peptide
  • Innate Immunity
  • Pulmonary Infection
  • Immunomodulation
  • Interferon
  • Antiviral
  • Vitamin D

Fingerprint Dive into the research topics of 'Cathelicidins have direct antiviral activity against respiratory syncytial virus in vitro and protective function in vivo in mice and humans.'. Together they form a unique fingerprint.

Cite this